A 24-week, Phase IIB, Randomized, Active-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis

Trial Profile

A 24-week, Phase IIB, Randomized, Active-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Daprodustat (Primary) ; Recombinant erythropoietin
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Aug 2015 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top